Replimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in November

Replimune Group, Inc. (NASDAQ:REPLGet Free Report) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily volume of 828,800 shares, the short-interest ratio is currently 6.7 days.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Replimune Group in the second quarter worth approximately $57,000. Arizona State Retirement System purchased a new stake in shares of Replimune Group during the second quarter valued at approximately $108,000. Quest Partners LLC increased its position in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Replimune Group in the 3rd quarter worth approximately $133,000. 92.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REPL. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Roth Mkm started coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Finally, BMO Capital Markets lifted their price objective on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $17.29.

Get Our Latest Analysis on Replimune Group

Replimune Group Trading Up 2.7 %

Shares of NASDAQ REPL opened at $12.55 on Monday. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The firm has a 50-day moving average of $12.19 and a 200 day moving average of $10.53. The stock has a market cap of $858.67 million, a P/E ratio of -4.11 and a beta of 1.26.

Replimune Group (NASDAQ:REPLGet Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group will post -2.91 EPS for the current fiscal year.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Read More

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.